In total, we identified heterozygous deleterious SPG7 variants in 9 of 214 (4.2%) European ALS patients and report on the predicted consequences of these variants on the protein level as well as on the clinical, electrophysiological, and neuroradiological characteristics of the variant carriers. The gene discussed is SPG7; the disease is amyotrophic lateral sclerosis.